Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
- Bhojwani D Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. dbhojwani@chla.usc.edu.
- Sposto R Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- Shah NN National Cancer Institute, Bethesda, MD, USA.
- Rodriguez V Mayo Clinic, Rochester, MN, USA.
- Yuan C National Cancer Institute, Bethesda, MD, USA.
- Stetler-Stevenson M National Cancer Institute, Bethesda, MD, USA.
- O'Brien MM Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA.
- McNeer JL University of Chicago Medicine Comer Children's Hospital, Chicago, IL, USA.
- Quereshi A Oxford University Hospitals, Oxford, UK.
- Cabannes A University Hospital Saint-Louis, Paris, France.
- Schlegel P University Children's Hospital of Würzburg, Würzburg, Germany.
- Rossig C University Children's Hospital of Münster, Münster, Germany.
- Dalla-Pozza L Children's Hospital at West-mead, Sydney, Australia.
- August K Children's Mercy Hospital, Kansas City, MO, USA.
- Alexander S The Hospital for Sick Children, Toronto, Canada.
- Bourquin JP University Children's Hospital, Zurich, Switzerland.
- Zwaan M Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
- Raetz EA New York University Langone Medical Center, New York, NY, USA.
- Loh ML Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
- Rheingold SR Childrens Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
- 2018-09-30
Published in:
- Leukemia. - 2019
Adolescent
Adult
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Child
Child, Preschool
Drug Resistance, Neoplasm
Female
Humans
Inotuzumab Ozogamicin
Male
Neoplasm Recurrence, Local
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
Remission Induction
Retrospective Studies
Salvage Therapy
Survival Rate
Young Adult
English
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%) patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted. Identification of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1038/s41375-018-0265-z
- PMID 30267011
- Persistent URL
- https://sonar.ch/global/documents/258895
Statistics
Document views: 14
File downloads:
- fulltext.pdf: 0